Patents by Inventor Elena Batienko

Elena Batienko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human IL1-R1 derived inhibitor of IL-1?
    Patent number: 11155600
    Abstract: A therapeutic composition is described that can be used for treating or prevention of diseases association with modulation of activity of human IL-1?. In certain aspects, the disclosed invention is based, on engineering of a heterodimeric protein assembly that is capable of binding to human IL-1? and attenuating its function. The heterodimeric protein assembly comprises extracellular portions of human IL1-R1 and of human IL-1RAcP, or their functional fragments. Each, the IL1-R1 portion and the IL-1RAcP portion, is fused to a distinct mutant of Fc portion of the human Ig Gamma-1. The two distinct Fc mutants in the heterodimeric protein assembly are engineered as to favor the heteromeric dimer formation between the two Fc mutants over any homomeric assembly. The therapeutic composition has been formulated for administration into humans and animals.
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: October 26, 2021
    Inventors: Yan Lavrovsky, Ting Xu, Elena Batienko, Anna Krotkova, Vasily Ignatiev, Mikhail Samsonov, Alexey Repik
  • Human IL1-R1 Derived Inhibitor of IL-1b
    Publication number: 20170226185
    Abstract: A therapeutic composition is described that can be used for treating or prevention of diseases association with modulation of activity of human IL-1?. In certain aspects, the disclosed invention is based, on engineering of a heterodimeric protein assembly that is capable of binding to human IL-1? and attenuating its function. The heterodimeric protein assembly comprises extracellular portions of human IL1-R1 and of human IL-1RAcP, or their functional fragments. Each, the IL1-R1 portion and the IL-1RAcP portion, is fused to a distinct mutant of Fc portion of the human Ig Gamma-1. The two distinct Fc mutants in the heterodimeric protein assembly are engineered as to favor the heteromeric dimer formation between the two Fc mutants over any homomeric assembly. The therapeutic composition has been formulated for administration into humans and animals.
    Type: Application
    Filed: March 24, 2014
    Publication date: August 10, 2017
    Inventors: Yan Lavrovsky, Ting Xu, Elena Batienko, Anna Krotkova, Vasily Ignatiev, Mikhail Samsonov, Alexey Repik